Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

bluebird bio, Inc. - Common Stock (NQ: BLUE )

4.080 -2.960 (-42.05%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 21, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about bluebird bio, Inc. - Common Stock

< Previous 1 2
...
15 16 17 18 19 20 21 22 Next >
Why Virios Therapeutics Is Trading Lower By Over 71%, Here Are 55 Stocks Moving In Monday's Mid-Day Session
Gainers MicroCloud Hologram Inc. (NASDAQ: HOLO) shares jumped 134.6% to $19.74. 
Via Benzinga
What's Going On With Bluebird Bio Stock Today?
Bluebird Bio Inc (NASDAQ: BLUE) shares are trading lower Monday. The stock initially surged in premarket trading following the U.S. Food and Drug Administration's accelerated approval of SKYSONA, but... 
Via Benzinga
AutoZone (AZO) Stock Pops as Sales Beat Expectations
AutoZone (AZO) stock is rising on Monday following the release of the automotive part company's earnings report for fiscal Q4 2022. 
Via InvestorPlace
What 4 Analyst Ratings Have To Say About bluebird bio
  Within the last quarter, bluebird bio (NASDAQ:BLUE) has observed the following analyst ratings: 
Via Benzinga
Bluebird's Gene Therapy Scores US Approval For Genetic Blood Disorder, Probably The Most Expensive
Via Benzinga
Bluebird Bio (BLUE) Stock Is in Focus Following FDA Approval
The Boston-based biotech company has secured FDA approval for one of its gene therapies. Let's take a closer look at BLUE stock. 
Via InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
We're starting off the week with a breakdown of the biggest pre-market stock movers for Monday morning and the news behind them! 
Via InvestorPlace
Why bluebird bio Is Trading Higher By Around 19%; Here Are 31 Stocks Moving Premarket
Gainers FOXO Technologies Inc. (NYSE: FOXO) rose 161% to $10.50 in pre-market trading after dipping 52% on Friday. 
Via Benzinga
US Stock Futures Down Ahead Of Fed's Rate Decision This Week, Crude Oil Drops Over 1%
Pre-open movers U.S. stock futures traded lower in early pre-market trade on Monday after recording losses on Friday. All the three major indices recorded losses last week, with the Dow Jones dropping... 
Via Benzinga
AutoZone, bluebird bio And 3 Stocks To Watch Heading Into Monday
With US stock futures trading lower this morning on Monday, some of the stocks that may grab investor focus today are as follows: 
Via Benzinga
FDA Okays bluebird bio's $3M Gene Therapy For Rare Neurological Disorder In Boys: What Investors Should Know
Biotechnology company, bluebird bio, Inc. (NASDAQ: BLUE) announced late Friday that the Food and Drug Administration approved its gene therapy for a rare neurodegenerative disease. 
Via Benzinga
bluebird bio Receives FDA Accelerated Approval for SKYSONA® Gene Therapy for Early, Active Cerebral Adrenoleukodystrophy (CALD)
From bluebird bio, Inc.
Via Business Wire
Something Unusual Is Happening Right Now With Biotech Stocks Like Catalyst, Vertex, Neurocrine And BioMarin
The market is struggling, yet biotech stocks are acting like it's good times again. Here's why. 
Via Investor's Business Daily
Jason Cole, Chief Strategy and Financial Officer, to Depart bluebird bio This Fall
From bluebird bio, Inc.
Via Business Wire
Bluebird bio Seeks Back-to-Back Nods, 'Go' or 'No-Go' For Revance's Botox Rival, Amylyx' Twin Hurdles And More: September's Key PDUFA Catalysts Biotech Investors Must Know
After August’s mixed tally for Food and Drug Administration approvals, investors turn to a new month, which has a fairly loaded calendar. 
Via Benzinga
10 Biotech Stocks Are Up 40% Or More This Year, Including Karuna, Axsome And Others
These names are benefitting from M&A, clinical data and promising regulatory actions. 
Via Investor's Business Daily
bluebird bio Announces September Investor Events
From bluebird bio, Inc.
Via Business Wire
Dear AAPL Stock Fans, Mark Your Calendars for Sept. 7
Fans of Apple (AAPL) stock will want to keep their calendars open for Sept. 7 as that's reportedly when its next event will take place. 
Via InvestorPlace
BLUE Stock Moves as FDA Approves Bluebird Bio’s Gene Therapy
Bluebird Bio (BLUE) stock is on the move Thursday following FDA approval for beta-thalassemia treatment ZYNTEGLO in adults and children. 
Via InvestorPlace
Bed Bath & Beyond, America's Car-Mart And Some Other Big Stocks Moving Lower On Thursday
  Bed Bath & Beyond Inc. (NASDAQ: BBBY) fell 23.3% to $17.71 following a Form 144 filing by RC Ventures, which suggested the firm proposed to sell 7.78 million common shares and certain call options.... 
Via Benzinga
This Biotechnology Stock Tumbled 37%; Here Are 70 Biggest Movers From Yesterday
Gainers Bright Minds Biosciences Inc. (NASDAQ: DRUG) shares climbed 135.9% to close at $2.17 on Thursday. 
Via Benzinga
Benzinga Before The Bell: Tesla Model Y Delivery Wait Time Shortened In China, Mark Zuckerberg's Sister Emphasizes On Evolution Of Web3, Amazon Succumbs To TikTok Fever And Other Top Financial Stories Thursday, August 18
CNBC 
Via Benzinga
Why Plus Therapeutics Is Trading Higher By Over 50%, Here Are 50 Stocks Moving In Thursday's Mid-Day Session
Gainers Bright Minds Biosciences Inc. (NASDAQ: DRUG) shares jumped 297% to $3.66. 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
  
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
It's time to take a look at the biggest pre-market stock movers for Thursday and the news that's got those shares moving! 
Via InvestorPlace
This Healthcare Stock Is Trading Lower By 29%: Here Are 29 Stocks Moving Premarket
Gainers 
Via Benzinga
Cisco, Keysight Technologies And Some Other Big Stocks Moving Higher In Today's Pre-Market Session
Wolfspeed, Inc. (NYSE: WOLF) rose 20.7% to $103.40 in pre-market trading after the company reported better-than-expected Q4 results. 
Via Benzinga
Recap Of Wednesday's Biotech Catalysts - End Of the Day Summary
Via Benzinga
Bluebird Secures FDA Nod For Genetic Blood Disease Candidate
The U.S. Food and Drug Administration (FDA) has approved Bluebird bio’s (NASDAQ: BLUE) lead asset ZYNTEGLO (betibeglogene autotemcel) to treat the underlying genetic cause of beta‑thalassemia in adult... 
Via Benzinga
bluebird bio Announces U.S. Commercial Infrastructure to Enable Patient Access to ZYNTEGLO®, the First and Only FDA-Approved Gene Therapy for People with Beta-Thalassemia Who Require Regular Red Blood Cell Transfusions
From bluebird bio, Inc.
Via Business Wire
< Previous 1 2
...
15 16 17 18 19 20 21 22 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.